Viewing nowCombinationGencarb Tablet 60/2.5mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Gunil Biopharm Co., Ltd.

MFDS item code 202300111 · Approved 2023.01.06 · Insurance code 073001550
Treatment of essential hypertension not controlled with fimasartan monotherapy
This drug is used for patients with essential hypertension who do not have adequate blood pressure control with monotherapy of Pimasartan potassium. In other words, it helps improve hypertension that is difficult to control with other treatments.
The recommended dose of this medication is 1 tablet once daily, taken with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). Before starting this medication, it is recommended to adjust the dose using fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medication may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams as monotherapy. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams as monotherapy or with this medication 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medication (a combination product containing the same amounts of each active ingredient) for convenience. No initial dose adjustment is needed for older adults aged 70 years or younger. No dose adjustment is needed in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment with this medication should be started with 30 milligrams of fimasartan. No dose adjustment is needed in patients with mild hepatic impairment; however, this medication should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy in pediatric and adolescent patients 18 years of age or younger have not been established.
This drug can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. This drug should not be administered to patients with allergies to its active ingredients or related components, those who are pregnant or breastfeeding, patients undergoing renal dialysis, those with moderate to severe liver disease, biliary obstruction, diabetic patients with certain kidney diseases, patients with genetic issues such as lactose intolerance, patients with severe aortic stenosis, and patients with symptoms of shock. Administration should be cautious in patients with low blood volume or salt levels, impaired kidney function, renal artery hypertension, and patients with aortic or mitral valve stenosis or obstructive heart disease, primary hyperaldosteronism, severe hypotension, elderly patients, and those with hypersensitivity to certain pigments. This medication may cause adverse reactions such as dizziness, headache, facial swelling, urinary difficulties, insomnia, and flushing. Rarely, severe kidney problems or blood pressure drops may occur; symptoms should be immediately discussed with a medical professional. Patients with hypotension or electrolyte imbalances should correct these conditions before taking this medication, and blood pressure and electrolyte levels should be monitored periodically during treatment. This drug can increase blood potassium levels; therefore, patients at risk for hyperkalemia should undergo regular blood tests. If taking this drug along with other antihypertensives, certain diuretics, or potassium supplements, interactions may occur, and this should be disclosed to the medical personnel. Women who are pregnant or breastfeeding should preferably avoid this medication, and in unavoidable cases, consultation with a specialist is necessary to decide on its use. Safety for children and adolescents under 18 years of age has not been established, so it is advisable not to use it. In case of overdose, severe hypotension, arrhythmias, and shock symptoms may occur; therefore, immediate emergency treatment is required. This medication should be kept out of reach of children and should not be transferred to other containers as this is better for maintaining quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that protects it from light and air, ideally at room temperature between 1 degree and 30 degrees Celsius. This way, the efficacy of the medication can be maintained and degradation can be prevented.
Yellow, rounded square film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Gunil Biopharm Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.